The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | INTerpath-002: pembrolizumab with a neoantigen therapy in completely resected NSCLC
Jay Lee, MD, UCLA Health, Los Angeles, CA, comments on the Phase III INTerpath-002 study (NCT06077760) of V940 (mRNA-4157), a novel individualized neoantigen therapy, with pembrolizumab in patients with completely resected and chemotherapy-treated stage II–IIIB non-small cell lung cancer (NSCLC). Building upon the IMpower010 (NCT02486718) and KEYNOTE-091 (NCT02504372) trials, eligible patients will receive V940 or placebo plus pembrolizumab, with disease-free survival as the primary endpoint. Secondary endpoints include distant metastasis-free survival, overall survival, and safety. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Moderna Therapeutics
Consulting or Advisory Role – AstraZeneca; Bristol Myers Squibb Foundation; Foundation Medicine; Genentech/Roche; Merck; Novartis; Regeneron
Speakers’ Bureau – AstraZeneca; Genentech/Roche
Research Funding – Bristol-Myers Squibb; Genentech/Roche; Novartis
Patents, Royalties, Other Intellectual Property – UCLA Patents
Travel, Accommodations, Expenses – Genentech/Roche; Genentech/Roche
(OPTIONAL) Uncompensated Relationships – Genentech/Roche; Novartis
